Insider Trades34 trades
| Date↓ | Side | Ticker↕ | Insider↕ | Role↕ | Shares↕ | Price↕ | Mkt Cap↕ | 52W High↕ | 52W Low↕ | Value↕ | % Chg↕ | Rule↕ | AI View↕ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | Sell | XFOR | David Kirske | Chief Financial Officer | 8,543 | $4.26 | $360.3M | -20.91% | +182.96% | $36.4K | -4.85% | — | — |
| May 12, 2026 | Sell | XFOR | David Kirske | Chief Financial Officer | 16,961 | $4.29 | $360.3M | -20.91% | +182.96% | $72.8K | -8.78% | — | — |
| Oct 23, 2025 | Buy | XFOR | Adam R Craig | Executive Chairman | 86,206 | $2.90 | $360.3M | -20.91% | +182.96% | $250.0K | +29.74% | — | — |
| May 16, 2025 | Buy | XFOR | Mark Baldry | Chief Commercial Officer | 1,032 | $2.48 | $360.3M | -20.91% | +182.96% | $2.6K | +4.25% | — | — |
| May 16, 2025 | Buy | XFOR | Mark Baldry | Chief Commercial Officer | 1,032 | $2.48 | $360.3M | -20.91% | +182.96% | $2.6K | +4.25% | — | — |
| Jan 24, 2025 | Sell | XFOR | Christophe Arbet-Engels | Chief Medical Officer | 11,624 | $0.45 | $360.3M | -20.91% | +182.96% | $5.3K | -45.00% | — | — |
| Jan 24, 2025 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 22,258 | $0.45 | $360.3M | -20.91% | +182.96% | $10.1K | -4.34% | — | — |
| Jan 24, 2025 | Sell | XFOR | Mark Baldry | Chief Commercial Officer | 29,159 | $0.45 | $360.3M | -20.91% | +182.96% | $13.2K | -23.65% | — | — |
| Jan 24, 2025 | Sell | XFOR | Adam S. Mostafa | Chief Financial Officer | 74,773 | $0.45 | $360.3M | -20.91% | +182.96% | $33.9K | -100.00% | — | — |
| Jan 24, 2025 | Sell | XFOR | Paula Ragan | President and CEO | 76,473 | $0.45 | $360.3M | -20.91% | +182.96% | $34.7K | -6.57% | — | — |
| Nov 15, 2024 | Sell | XFOR | Paula Ragan | President and CEO | 31,897 | $0.39 | $360.3M | -20.91% | +182.96% | $12.6K | -3.11% | — | — |
| Oct 15, 2024 | Sell | XFOR | Paula Ragan | President and CEO | 31,897 | $0.56 | $360.3M | -20.91% | +182.96% | $17.9K | -3.02% | — | — |
| Oct 7, 2024 | Sell | XFOR | Mark Baldry | Chief Commercial Officer | 11,127 | $0.58 | $360.3M | -20.91% | +182.96% | $6.5K | -18.66% | — | — |
| Oct 7, 2024 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 67,695 | $0.57 | $360.3M | -20.91% | +182.96% | $38.3K | -13.02% | — | — |
| Oct 7, 2024 | Sell | XFOR | Arthur Taveras | Chief Scientific Officer | 76,920 | $0.56 | $360.3M | -20.91% | +182.96% | $43.3K | -16.54% | — | — |
| Oct 7, 2024 | Sell | XFOR | Adam S. Mostafa | Chief Financial Officer | 230,645 | $0.55 | $360.3M | -20.91% | +182.96% | $126.9K | -100.00% | — | — |
| Oct 7, 2024 | Sell | XFOR | Paula Ragan | President and CEO | 239,436 | $0.55 | $360.3M | -20.91% | +182.96% | $131.5K | -18.46% | — | — |
| Sep 9, 2024 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 2,642 | $0.66 | $360.3M | -20.91% | +182.96% | $1.7K | -0.91% | — | — |
| May 17, 2024 | Buy | XFOR | Mark Baldry | Chief Commercial Officer | 35,050 | $0.55 | $360.3M | -20.91% | +182.96% | $19.3K | +16.70% | — | — |
| Mar 11, 2024 | Sell | XFOR | Arthur Taveras | Chief Scientific Officer | 14,235 | $0.88 | $360.3M | -20.91% | +182.96% | $12.6K | -5.73% | — | — |
| Mar 11, 2024 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 15,409 | $0.88 | $360.3M | -20.91% | +182.96% | $13.6K | -5.02% | — | — |
| Mar 11, 2024 | Sell | XFOR | Paula Ragan | President and CEO | 49,678 | $0.88 | $360.3M | -20.91% | +182.96% | $43.9K | -6.10% | — | — |
| Mar 11, 2024 | Sell | XFOR | Adam S. Mostafa | Chief Financial Officer | 52,500 | $0.88 | $360.3M | -20.91% | +182.96% | $46.3K | -100.00% | — | — |
| Feb 12, 2024 | Sell | XFOR | Arthur Taveras | Chief Scientific Officer | 787 | $1.01 | $360.3M | -20.91% | +182.96% | $792.666 | -0.32% | — | — |
| Feb 12, 2024 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 3,683 | $1.01 | $360.3M | -20.91% | +182.96% | $3.7K | -1.18% | — | — |
| Feb 12, 2024 | Sell | XFOR | Paula Ragan | President and CEO | 21,695 | $1.01 | $360.3M | -20.91% | +182.96% | $21.9K | -2.59% | 10b5-1 | — |
| Feb 12, 2024 | Sell | XFOR | Adam S. Mostafa | Chief Financial Officer | 27,721 | $1.01 | $360.3M | -20.91% | +182.96% | $28.0K | -34.56% | 10b5-1 | — |
| Nov 1, 2023 | Sell | XFOR | Mark Baldry | Chief Commercial Officer | 10,257 | $0.73 | $360.3M | -20.91% | +182.96% | $7.5K | -29.35% | 10b5-1 | — |
| Nov 1, 2023 | Sell | XFOR | Arthur Taveras | Chief Scientific Officer | 67,695 | $0.73 | $360.3M | -20.91% | +182.96% | $49.4K | -21.35% | 10b5-1 | — |
| Nov 1, 2023 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 67,695 | $0.73 | $360.3M | -20.91% | +182.96% | $49.4K | -17.88% | 10b5-1 | — |
| Nov 1, 2023 | Sell | XFOR | Adam S. Mostafa | Chief Financial Officer | 230,645 | $0.73 | $360.3M | -20.91% | +182.96% | $168.4K | -74.19% | 10b5-1 | — |
| Nov 1, 2023 | Sell | XFOR | Paula Ragan | President and CEO | 239,437 | $0.76 | $360.3M | -20.91% | +182.96% | $181.6K | -12.26% | 10b5-1 | — |
| Sep 8, 2023 | Sell | XFOR | Mary Dibiase | Chief Operating Officer | 2,642 | $1.25 | $360.3M | -20.91% | +182.96% | $3.3K | -1.76% | 10b5-1 | — |
| Aug 10, 2023 | Sell | XFOR | Murray Stewart | Interim Chief Medical Officer | 130,056 | $1.06 | $360.3M | -20.91% | +182.96% | $137.9K | -47.03% | — | — |